H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $42 from $40 and keeps a Buy rating on the shares. The top-line results from the pivotal Phase 3 FURVENT trial are expected in early 2026, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma price target lowered to $33 from $40 at Citi
- ArriVent BioPharma Advances Cancer Therapeutics Pipeline
- Positive Growth Trajectory and Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Clinical Data and Strategic Development
- ArriVent Biopharma reports Q2 EPS (90c), consensus (71c)
- ArriVent Biopharma sees cash runway into mid-2027